Tendinopathies and osteoarthritis (OA) are extremely common and these injuries associate with high health and socioeconomic costs, long-term postoperative rehabilitation, and loss of productivity. To date, none of the existing surgical or non-surgical alternatives have provided a successful long-term effect, and often the treated tissues do not restore their complete strength and functionality. To fill the critical gap of proper treatments TRiAnkle proposes to develop 3D bioprinted scaffolds based on collagen and gelatine, functionalised with stem cells and/or nanoencapsulated regenerative factors. The surgical implantation of these new functionalised biomaterials will enable the targeted delivery of the mentioned biologically active agents to promote cell growth and differentiation to enable better and faster regeneration of injured collagen-rich tissues like articular cartilage, ligament and tendon of the ankle. Two case-studies will be implemented: the partial rupture (>50%) of Achilles tendon and osteochondral cartilage injuries, which will serve as a technological platform to deliver new regenerative therapies for any other articular, tendinous or ligament diseases of weight-bearing joints. By achieving this goal, TRiAnkle will enable, in comparison with current surgical treatments: - To increase by 10-15% of the ankle joints functionality recovery ratios due to the presence of pro-regenerative components that promote the healing process decreasing also the risk of re-rupture or recidivation. - To reduce the recovery time and the associated healthcare costs up to 50% due to the use of scaffolds that mimic the natural structure and mechanical properties of joint tissues. TRiAnkle will be implemented by a multidisciplinary team made up of biomaterial production companies, manufacturing technologies experts, material engineers, preclinical validation centers, healthcare professionals, patients associations and experts in ethical, regulatory and exploitation.

PREVENTOMICS builds a new paradigm in preventive personalised nutrition based on the potential of omics, especially metabolomics, accessible for everyone. The novelty relies on a new integration of genetic, nutritional and psychological factors and the application of state of the art metabolomics technologies and computational modelling of the metabolome, to assess the real incidence of disease-inducing factors on the organism, translating this information into personalized dietetic advice for the user, levering on ICT technologies. The main outcome from PREVENTOMICS is a novel mFood Platform, a unique-in-its-kind service, interoperable with current existing Apps for monitoring health status and with personalized nutrition software, thus opening the door to the personalization of any type of health treatment where combinations of genetic, biological, nutritional and psychological factors are important. PREVENTOMICS will be validated in 3 different case scenarios, performing relevant interventional studies with healthy and obese volunteers, to demonstrate its potential for personalization of nutrition at the 3 levels of the food value chain (processing and distribution, marketing and consuming), those closest to the end-users/consumers. Maximum impact will be ensured through well-balanced dissemination, standardarisation, communication and by the exploitation of the mFood platform, the menu recommendations, the personalised food elaboration and delivery, the food ingredients for personalised food and the personalised food shopping offer available for personal self-care and for professional services.